Springe zum Hauptteil

Immunomonitoring & Cancer Immunology Research Group
Section for Clinical Bioinformatics
Internal Medicine I
University Medical Center Tübingen

Development of cancer usually occurs in later life through uncontrolled growth of mutated cells that are escaping immunosurveillance - a multi-facetted process of interactions between tissues and immune cells. Selective manipulation of some of these regulatory circuits led to the groundbreaking success of immune checkpoint blockade, first for the treatment of melanoma, and in the meantime for increasing numbers of other solid tumors. However, not all patients benefit from these therapies underlining the urgent need to better understand the mechanisms behind immune checkpoint blockade.

We are interested in the construction of models predicting the outcome of immune checkpoint blockade by combining immunomonitoring and clinical meta data in melanoma. Furthermore, we aim to contribute to a better understanding of the interplay between the immune system and the tumor through phenotypic and functional investigations of different peripheral and tumor-invasive T-cell subsets, as well as immune suppressors. 

As a member of the DFG FOR2799 “Receiving and translating signals via the gamma/delta T-cell receptor", a major focus of our research is the investigation of the role of gamma/delta T-cells in cancer rejection under immune checkpoint blockade. 

DFG Gepris - FOR2799


„Receiving and Translating Signals via the γδ T Cell Receptor“

FOR 2799


We are interested in the identification and functional investigation of shared T-cell signatures predicting the recognition of tumor-associated antigens (TAAs) before and under immune checkpoint blockade to translate this to novel therapeutic approaches.

The collaboration with the Berlin Aging Study-II aims at distinguishing immune parameters of aging from cancer-associated features, as the occurrence of solid cancer is usually limited to older individuals

BASE II

The CIMT (Association for Cancer Immunotherapy) Immunoguiding Program (CIP) guides the development of innvovative cancer  immunotherapeutics through inter-laboratory harmonization and quality  control education.

Further Information

Publications

Dynamics of melanoma-associated epitope-specific CD8+ T cells in the blood correlate with clinical outcome under PD-1 blockade
Gaißler A, Meldgaard TS, Heeke C, Babaei S, Tvingsholm SA, Bochem J, Spreuer J, Amaral T, Wagner NB, Klein R, Meier F, Garbe C, Eigentler TK, Pawelec G, Claassen M, Weide B, Reker Hadrup S, Wistuba-Hamprecht K Frontiers in Immunology. 2022 May

Integrin activation enables rapid detection of functional Vδ1+ and Vδ2+ γδ T cells
Herold N, Schöllhorn A, Feile A, Gaissler A, Mohrholz A, Pawelec G, Löffler MW, Dimitrov S, Gouttefangeas C, Wistuba-Hamprecht K European Journal of Immunology. 2022 Feb. doi: 10.1002/eji.202149682

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Bochem J, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Konigsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Loeffler MW, Weide B, Wistuba-Hamprecht K
Journal for Immunotherapy of Cancer. 2021 Dec;9(12):e003439. doi: 10.1136/jitc-2021-003439.

Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation
Lazar K, Kussmann T, Pawelec G, Pöschel S, Goelz R, Hamprecht K, Wistuba-Hamprecht K
Frontiers in Immunology. 2021 Sep 9;12:723010. doi: 10.3389/fimmu.2021.723010.

Genetic influence on the peripheral differentiation signature of Vδ2+ γδ and CD4+ αβ T Cells in adults
Beucke N, Wingerter S, Hähnel K, Larsen LA, Christensen K, Pawelec K, Wistuba-Hamprecht K
Cells. 2021 Feb 11;10(2):373. doi: 10.3390/cells10020373.

Immune signatures and survival of patients with metastatic melanoma, renal cancer and breast cancer
Wistuba-Hamprecht K, Gouttefangeas C, Weide B, Pawelec G
Frontiers in immunology. 2020 Jun 9;11:1152. doi: 10.3389/fimmu.2020.01152.

Accurate determination of γδ T cells in multi-channel mass and flow cytometry
Beucke N, Wistuba-Hamprecht K 
Clinical Cytometry: part B. 2021 May;100(3):288-289. doi: 10.1002/cyto.b.21885.

Pitfalls in the characterization of circulating and tissue-resident human γδ T cells
Beucke N, Wesch D, Oberg H H, Peters C, Bochem J, Weide B, Garbe C, Pawelec G, Sebens S, Röcken C, Hashimoto H, Nocerino P, Löffler MW, Kordasti S, Kabelitz, D, Schilbach K, Wistuba-Hamprecht K
Journal of Leukocyte Biology. 2020 Jun;107(6):1097-1105. doi: 10.1002/JLB.5MA1219-296R.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K,
PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301.

Group Members

Dr. rer. nat. Kilian Wistuba-Hamprecht

Dr. rer. nat. Kilian Wistuba-Hamprecht

Gruppenleiter

Telefonnummer: 07071 29-89639

Telefonnummer: +49-7071-29-89639

E-Mail-Adresse: kilian.wistuba-hamprecht@uni-tuebingen.de

Publikationen: Publikationen

Personenprofil: Mehr zur Person

Andrea Gaißler

M.Sc. Tech. Biol. ; PhD student

E-Mail-Adresse: andrea.gaissler@med.uni-tuebingen.de

Nicola Beucke

M.Sc. Biochem. ; PhD student

E-Mail-Adresse: nicola.beucke@med.uni-tuebingen.de

Jonas Bochem

M.Sc. Biol.

E-Mail-Adresse: jonas.bochem@student.uni-tuebingen.de

Janine Spreuer

B.Sc. Biol. ; BTA

E-Mail-Adresse: janine.spreuer@med.uni-tuebingen.de

Jakob Brandstetter

B.Sc.Biol.

E-Mail-Adresse: jakob.brandstetter@student.uni-tuebingen.de

Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
 
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.

Zurück

Cookies zulassen Nur notwendige Cookies zulassen